Index of drugs

Treatment of non-infectious inflammatory diseases of the eyes that respond to corticosteroids, such as inflammation of the conjunctival and palpebral conjunctiva, cornea and anterior segment of the eyeball.

1 ml of suspension contains 1 mg fluorometholone.

Synthetic corticosteroid with a strong anti-inflammatory effect in the form of an ophthalmic preparation. Anti-inflammatory effects result from inhibition of vascular endothelial adhesion factors, COX I or II, and cytokine expression. There is a decrease in the effect of inflammation mediators and inhibition of leukocyte adhesion to the vascular endothelium, which prevents their penetration into the tissue of the affected eye. Corticosteroids may cause increased intraocular pressure in some susceptible patients; the preparation has a lower intraocular pressure lowering effect than Dexamethasone phosphate. After administration to the eye, the drug is well absorbed and distributed in the cornea and aqueous humor.

Hypersensitivity to the components of the preparation. acute untreated bacterial infections. Herpetic keratitis. Krowianka, chickenpox and other viral infections of the cornea or conjunctiva. Fungal diseases of eye structures. Mycobacterium infections of the eye. Untreated purulent ocular infection.

The safety and efficacy of the preparation in children aged <3 years has not been established. Patients who require long-term use of ocular corticosteroids should often monitor intraocular pressure. The risk of developing intraocular hypertension and cataract formation is greater in patients with diabetes and children. When used in patients with glaucoma, the drug should be used no longer than 2 weeks, except when longer treatment is warranted; the intraocular pressure should be monitored. Corticosteroids may facilitate the development of bacterial, fungal or viral infections and mask the clinical signs of infection. In cases of persistent ulceration of the cornea that has occurred after steroid treatment, the possibility of fungal infection should always be considered. You should stop taking the medicine if you have fungal infections. In patients with diseases leading to thinning of the cornea or sclera, the occurrence of perforation during topical corticosteroid use has been observed. In addition, steroids may delay the healing of corneal damage. The risk of healing problems increases with the simultaneous, topical use of NSAIDs. Take special care when using the drug in a virus infectionherpes simplex. The use of corticosteroid therapy in the treatment of herpes other than herpetic corneal epithelium, where it is contraindicated, requires special care; periodic microscopic examination in a slit lamp is necessary. The city's administration of steroids may be accompanied by a decrease in cortisol secretion in the urine as well as a decrease in blood cortisol. A corticosteroid relationship has been observed with a reduction in the rate of growth in children, especially at high doses and long-term treatment. Do not stop treatment with the product prematurely. Abrupt discontinuation of steroid therapy that is topically applied to the eye at high doses may cause worsening of the eye disease that occurs with inflammation. The drops contain benzalkonium chloride, which may cause eye irritation and discoloration of soft contact lenses; the contact lenses should be removed before instillation; they can be put on again 15 minutes after instillation. Patients should be advised that contact lenses should not be used if eye infections are present.

During pregnancy, use only if the anticipated benefits to the mother outweigh the potential risk to the fetus. It is not known whether fluorometholon or its metabolites are excreted in human milk when topically administered to the eye. Systemic corticosteroids are excreted in human milk. A risk to a breast-fed infant can not be excluded.

The following may occur: increased intraocular pressure, eye pain, eye irritation, discomfort in the eye, feeling of a foreign body in the eye, blurred vision, congestion of the eye, increased tearing, dysgeusia. Long-term topical (to the eye) use of corticosteroids may result in increased intraocular pressure with damage to the optic nerve, reduced visual acuity and visual field disorders, as well as subcapsular cataract formation and delayed wound healing. When using a combination therapy with corticosteroids, secondary infections may occur. There is a risk of perforation in the case of diseases that lead to thinning of the cornea or sclera.

Adults (including the elderly) and adolescents: 1 drop into the conjunctival sac of the affected eye (eyes) 2-4 times a day. During the first 24-48 hours, the dosage may be increased by administering 1 drop every 4 hours. After instillation, gently close the eyelid and compress the nasolabial duct to reduce systemic absorption. If you use more than one eye medicine, each of these medicines should be given at least 10-15 minutes apart. Eye Ointment should be used as the last one.